Pipelines

Dementia research lags behind the disease burden, says the WHO report. Pic: getty/nopparit

How can dementia drug development be improved?

By Rachel Arthur

The WHO has set out a new blueprint for dementia research: outlining the potential of precision medicine, repurposed drugs and revamped clinical trials. “Addressing dementia is one of the greatest health challenges of our generation,” says the organization.

Pic:getty/maxiphoto

Catalent buys UK vaccine manufacturing centre

By Rachel Arthur

US company Catalent is acquiring the UK’s Vaccine Manufacturing and Innovation Centre in Harwell: a facility which had been planned to support COVID-19 and wider vaccine production and which is still under construction.

© GettyImages/Cecilie_Arcurs

Novartis inks contract manufacturing deal with Carisma

By Jane Byrne

Novartis continues down the third-party manufacturing route, as it secures an agreement with Carisma Therapeutics, a firm developing a cell therapy platform focused on engineered macrophage-based therapeutics.

Pic:getty/coffeekai

Moderna initiates Phase 3 trial for RSV vaccine candidate

By Rachel Arthur

Moderna has initiated the Phase 3 portion of its pivotal respiratory syncytial virus (RSV) vaccine trial: looking towards its ultimate goal to combine the vaccine with its COVID-19 and flu boosters into a single dose booster.

© GettyImages/Martin Barraud

4D Pharma sees positive data from early stage asthma trial

By Jane Byrne

Live biotherapeutic product (LBP) developer, 4D Pharma, which has been NASDAQ listed since March this year, has announced positive topline results for the first part of its Phase I/II trial of an LBP strain for the treatment of asthma.

© GettyImages/Monty Rakusen

Lonza and Doer Biologics in expression system license deal

By Jane Byrne

Lonza has signed a licensing agreement with clinical-stage biopharma, Zhejiang Doer Biologics, whereby the Hangzhou, China based biopharma company will develop multi-specific biotherapeutics using the Swiss CDMO’s XS Pichia.

© GettyImages/PonyWang

Sphere Fluidics closes $40m funding round

By Jane Byrne

Sphere Fluidics, a UK company that has developed and is commercializing single cell analysis systems underpinned by its picodroplet technology, has just closed a US$40m investment round.

Follow us

Products

View more

Webinars